Bevacizumab in the treatment of high-grade gliomas: An overview

Keyphrases

• Bevacizumab 100%
• High-grade Glioma 100%
• Quality of Life 50%
• Angiogenesis 50%
• Clinical Trials 50%
• Vascular Endothelial Growth Factor 50%
• Monoclonal Antibody 50%
• Therapeutic Agents 50%
• Newly Diagnosed 50%
• Overall Survival 50%
• Glioma 50%
• Dose Timing 50%
• Relapse Pattern 50%
• Radiological Response 50%
• Unanswerable Questions 50%

Biochemistry, Genetics and Molecular Biology

• Bevacizumab 100%
• Angiogenesis 50%
• Morbidity 50%
• Vascular Endothelial Growth Factor 50%
• Monoclonal Antibody 50%
• Clinical Trial 50%
• Overall Survival 50%

Immunology and Microbiology

• Bevacizumab 100%
• Angiogenesis 50%
• Vasculotropin 50%
• Monoclonal Antibody 50%
• Morbidity 50%
• Overall Survival 50%